Skip to main content
Year archive

FARON PHARMACEUTICALS OY — 2023 filings

All 54 regulatory filings released by FARON PHARMACEUTICALS OY (FARN) in 2023, sourced directly from the official regulator.

54 Filings
2023 Period
2023 filings (54)
Filing Released Lang
Faron’s Financial Calendar for 2024
Report Publication Announcement
2023-12-22 English
Phase 1 BEXMAB data presented at ASH
Regulatory Filings
2023-12-11 English
MATINS Trial in Cell Reports Medicine
Earnings Release FY 2023
2023-12-07 English
Grant of options
Director's Dealing
2023-12-04 English
Faron Initiates Phase 2 Part of BEXMAB Study
Legal Proceedings Report
2023-11-06 English
Faron Initiates Phase 2 Part of BEXMAB Study
Regulatory Filings
2023-11-06 English
Faron to present data from BEXMAB study at ASH
Regulatory Filings
2023-11-02 English
Manager's transactions
Director's Dealing
2023-10-27 English
Exercise of options
Share Issue/Capital Change
2023-10-27 English
Results of Placing
Capital/Financing Update
2023-10-27 English
Proposed Issue and Placing
Capital/Financing Update
2023-10-26 English
Faron Announces Positive BEXMAB Study Update
Regulatory Filings
2023-10-11 English
Faron to host webcast on new BEXMAB study data
Report Publication Announcement
2023-10-03 English
Board Changes
Board/Management Information
2023-09-22 English
Results of EGM
AGM Information
2023-09-22 English
Faron Appoints Interim Chief Medical Officer
Regulatory Filings
2023-09-21 English
Change in the Board of Directors
Board/Management Information
2023-09-08 English
Faron to Present at H.C. Wainwright Conference
Report Publication Announcement
2023-09-06 English
Notice of EGM
AGM Information
2023-09-01 English
Exercise of options
Director's Dealing
2023-08-31 English
Faron 2023 Half-Year Financial Results
Interim / Quarterly Report H1 2023
2023-08-29 English
FDA Orphan Drug Designation for Bexmarilimab
Earnings Release Q4 2023
2023-08-29 English
Notice of Half-Year Financial Results
Report Publication Announcement
2023-08-04 English
Faron to Participate at Canaccord Conference
Regulatory Filings
2023-08-02 English
Grant of Options
Director's Dealing
2023-07-25 English
Faron to Hold BEXMAB Study Conference Call
Earnings Release Q3 2023
2023-07-19 English
BEXMAB study update
Legal Proceedings Report
2023-07-19 English
Holding(s) in Company
Major Shareholding Notification
2023-06-30 English
Announcement of Placing
Share Issue/Capital Change
2023-06-29 English
Exercise of options
Share Issue/Capital Change
2023-06-12 English
New biomarker data from BEXMAB study at EHA2023
Earnings Release Q2 2023
2023-06-09 English
Board Member to Assume Transactional Advisor Role
Regulatory Filings
2023-06-05 English
Bexmarilimab Efficacy and Safety in MATINS Trial
Regulatory Filings
2023-04-24 English
Bexmarilimab KOL Event
Regulatory Filings
2023-04-19 English
Poster Presentations at AACR 2023
Regulatory Filings
2023-04-18 English
BEXMAB study update
Regulatory Filings
2023-04-17 English
Faron at Canaccord Oncology Virtual Conference
Regulatory Filings
2023-04-13 English
Appointment of Chief Financial Officer
Board/Management Information
2023-03-29 English
Board Change
Board/Management Information
2023-03-24 English
Results of AGM
AGM Information
2023-03-24 English
Positive FDA Feedback to Progress Bexmarilimab
Regulatory Filings
2023-03-22 English
Notice of Faron Pharmaceuticals Ltd’s AGM
AGM Information
2023-03-03 English
Faron´s Annual Report 2022 Published
Report Publication Announcement
2023-03-03 English
Financial Statement January 1 to December 31 2022
Annual Report FY 2022
2023-03-03 English
Update to Faron’s Financial Calendar for 2023
Regulatory Filings
2023-02-06 English
Notice of 2022 Full-Year Results and Annual Report
Report Publication Announcement
2023-02-06 English
Holding(s) in Company
Major Shareholding Notification
2023-02-01 English
Holding(s) in Company
Major Shareholding Notification
2023-01-27 English
Results of Placing
Capital/Financing Update
2023-01-27 English
Proposed Issue and Placing
Capital/Financing Update
2023-01-26 English
Price Monitoring Extension
Regulatory Filings
2023-01-16 English
Second Price Monitoring Extn
Regulatory Filings
2023-01-16 English
Price Monitoring Extension
Regulatory Filings
2023-01-16 English
Title: BEXMAB study update
Earnings Release Q1 2023
2023-01-16 English